Bristol-Myers Squibb Co  

(Public, NYSE:BMY)   Watch this stock  
Find more results for BMY
65.86
+0.51 (0.78%)
After Hours: 66.05 +0.19 (0.29%)
Apr 20, 7:15PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 65.24 - 66.25
52 week 46.30 - 69.20
Open 65.73
Vol / Avg. 9.36M/6.27M
Mkt cap 109.10B
P/E 54.82
Div/yield 0.37/2.25
EPS 1.20
Shares 1.66B
Beta 0.27
Inst. own 73%
May 5, 2015
Bristol-Myers Squibb Co Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
Apr 28, 2015
Q1 2015 Bristol-Myers Squibb Co Earnings Call - 11:00AM EDT - Add to calendar
Apr 28, 2015
Q1 2015 Bristol-Myers Squibb Co Earnings Release - 9:30AM EDT - Add to calendar
Mar 3, 2015
Bristol-Myers Squibb Co at Cowen Health Care Conference
Feb 12, 2015
Bristol-Myers Squibb Co at Leerink Global Healthcare Conference
Jan 27, 2015
Q4 2014 Bristol-Myers Squibb Co Earnings Release
Jan 27, 2015
Q4 2014 Bristol-Myers Squibb Co Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 0.63% 12.78%
Operating margin -1.41% 11.41%
EBITD margin - 24.69%
Return on average assets 0.32% 5.61%
Return on average equity 0.35% 13.36%
Employees 25,000 -
CDP Score - 98 B

Address

345 PARK AVE
NEW YORK, NY 10154
United States - Map
+1-212-5464000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. The Company's products are sold across the world, to wholesalers, retail pharmacies, hospitals, Government entities and the medical profession. It manufactures products in the United States, Puerto Rico and in over six foreign countries. Its pharmaceutical products include chemically-synthesized drugs or small molecules, and products produced from biological processes. Its products in therapeutic classes: virology, including human immunodeficiency virus (HIV) infection; oncology; neuroscience; metabolics; immunoscience, and cardiovascular. Its product F001287 is a preclinical, small-molecule IDO1-inhibitor. It offers an indoleamine 2, 3-dioxygenase (IDO) or tryptophan 2, 3-dioxygenase (TDO) discovery program that includes its IDO-selective, IDO/TDO dual and TDO-selective compound libraries.

Officers and directors

Charles A. Bancroft Chief Financial Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
Louis S Schmukler President - Global Manufacturing and Supply
Age: 59
Bio & Compensation  - Reuters
Giovanni Caforio M.D. Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Francis M. Cuss Executive Vice President, Chief Scientific Officer
Age: 60
Bio & Compensation  - Reuters
Sandra Leung Executive Vice President, General Counsel and Corporate Secretary
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Paul von Autenried Senior Vice President - Enterprise Services, Chief Information Officer
Age: 53
Bio & Compensation  - Reuters
Anne Nielsen Senior Vice President, Chief Compliance and Ethics Officer
Age: 54
Bio & Compensation  - Reuters
Joseph C. Caldarella Senior Vice President, Corporate Controller
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ann Powell Judge Senior Vice President - Global Human Resources
Age: 49
Bio & Compensation  - Reuters
John E. Elicker Senior Vice President - Public Affairs
Age: 55
Bio & Compensation  - Reuters